进入财报季，各个公司逐渐交出了2025年的业绩答卷。 2月26日，AI制药的两大头部玩家——薛定谔（Schrödinger）和“英伟达概念股”Recursion罕见地在同一天发布财报。

刚刚过去的2月，全球AI制药行业可谓是“腥风血雨”。 先是在2月18日，英伟达提交的“13F文件”显示，已在2025年第四季度清仓其持有的全部Recursion股份，正式宣告撤退。 紧接着在2月26日，AI制药两大头部企业Schrödinger和Recursion罕见的在同一天发布2025年财报，但业绩都不太好看：Schrödinge虽然营收增长23.3%，但全年净亏损仍然高达1.033亿美元：R ...

Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI ...

If you are wondering whether Recursion Pharmaceuticals is a bargain or a value trap at its current share price, this article will walk you through how its valuation stacks up using several common ...

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the stocks Jim Cramer answered questions about. When a caller ...

Recursion Pharmaceuticals is helping pioneer the use of AI in drug discovery. The company's operating system tests ...

加利福尼亚州门洛帕克 - PacBio (NASDAQ:PACB)今日发布新闻稿宣布,任命Christopher Gibson博士加入其董事会。 Gibson是临床阶段生物技术公司Recursion (NASDAQ:RXRX)的联合创始人兼董事会主席。在Recursion,他领导开发了一个将生物数据生成与机器学习相结合的药物发现平台。他带领公司完成了募集资金、战略合作伙伴关系建立以及公开上市。 P ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Nvidia’s forthright ambitions to expand its drug development footprint are coming into focus, with the global computing powerhouse announcing a trio of new initiatives including a new collaboration ...

Shares of Recursion Pharmaceuticals are down by about 47% from a peak the stock set this February. The company uses automation and artificial intelligence to optimize the new drug-discovery process.

Recursion Pharmaceuticals, Inc. ( RXRX) TD Cowen 46th Annual Health Care Conference March 2, 2026 9:50 AM EST All right. Good morning, again, for I see some familiar face in the last one, but thanks ...

This Q&A is part of a weekly series of posts highlighting common questions encountered by technophiles and answered by users at Stack Exchange, a free, community-powered network of 100+ Q&A sites.